"Our Flow Cytometry MRD for Myeloma test harnesses cutting-edge science and technology to deliver ultrasensitive insights from a noninvasive blood test, thereby improving care and value for patients ...
Becton, Dickinson and Company BDX, popularly known as BD, recently announced the global commercial launch of BD Research Cloud 7.0, marking another step forward in its AI-driven life sciences strategy ...
Flow cytometry offers practical advantages for real-time monitoring of CAR T cell expansion, persistence, and toxicity risk in aggressive large B-cell lymphoma patients. Early CAR T cell expansion is ...
How do we “name” a cell and assign its identity? How do we know that we are all talking about the same cells? How do we agree on what it takes to confidently correlate previous with current research ...
Flow cytometry effectively detects CTCs in melanoma patients, offering a rapid, cost-effective alternative to molecular biology. CTCs are present across all melanoma stages, with a significant ...
A research team from George R Brown School of Engineering and Computing (Rice University; TX, USA), led by Peter Lillehoj and Kevin Mchugh, have developed an innovative AI-enabled microfluidic ...
Flow cytometry has become a key analytical technique in clinical trials. Through its multiparametric analysis, single-cell resolution, and high-throughput evaluation capabilities, flow cytometry can ...
FRANKLIN LAKES, N.J. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company (BDX)), a leading global medical technology company, and Biosero, a developer of laboratory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results